Literature DB >> 26914377

Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.

Juan L Coelho-Silva1, Luany E Carvalho2, Mayara M Oliveira1, Pedro L Franca-Neto1, Adryanna T Andrade1, Aleide S Lima1, Matheus F Bezerra1, Marinus M Lima3, Maria A Neves4, Julia M Fonseca4, Maria C Barros-Correia4, Cintia G Machado4, Marcos A Bezerra1, Daniel M Matos2, Antonio R Lucena-Araujo1.   

Abstract

Entities:  

Keywords:  Acute myeloid leukaemia; CD56 expression; developing countries; prognostic factors; treatment outcome

Mesh：

Substances：

Year:  2016        PMID： 26914377     DOI： 10.1111/bjh.13971

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.

Authors:  Matheus F Bezerra; Juan L Coelho-Silva; Jessica C Nascimento; Mariana T Benicio; Cintia R Rocha; Cintia G Machado; Eduardo M Rego; Marcos A Bezerra; Antonio R Lucena-Araujo; Eduardo I Beltrão
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

2.  High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.

Authors:  Wen Du; Jing He; Wei Zhou; Simin Shu; Juan Li; Wei Liu; Yun Deng; Cong Lu; Shengyan Lin; Yaokun Ma; Yanli He; Jine Zheng; Jiang Zhu; Lijuan Bai; Xiaoqing Li; Junxia Yao; Dan Hu; Shengqing Gu; Huiyu Li; Anyuan Guo; Shiang Huang; Xiaolan Feng; Dong Hu
Journal:  J Transl Med       Date:  2019-06-06       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.